Search
Methylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalMethylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. … FDA approved in 2008.
Tolfenamic acid
go.drugbank.com/drugs/DB09216Approved[A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. … [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSClozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigational[L905] Due to its severe adverse effects profile, clozapine is only available through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.[L905] … Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.
Products: Gen-clozapineCalcium glubionate anhydrous
go.drugbank.com/drugs/DB13142ApprovedCalcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalInavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials. … [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Categories: Drugs Used in Hereditary AngioedemaImiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas.
International brands: Nan BoClomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Synonyms: 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamineDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalAtrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. … [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009.
Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide